Table 1.
PEGen and PSGen genes isolated by using RSDD
| Nomenclature* | Identity† | Homology,‡ % |
|---|---|---|
| PEGen 7 | Human HPV16 E1BP | 90 |
| PEGen 8 | PFK-C | 100 |
| PEGen 13 | Unknown | Novel |
| PEGen 14 | Unknown | Novel |
| PEGen 21 | Murine FIN 14 | 94 |
| PEGen 24 | Unknown | Novel |
| PEGen 26 | PARP | 100 |
| PEGen 28 | Unknown | Novel |
| PEGen 30 | Rat esp1 | 98 |
| PEGen 32 | Unknown | Novel |
| PSGen 12 | Unknown | Novel |
| PSGen 13 | Unknown | Novel |
| PSGen 26 | Unknown | Novel |
| PSGen 27 | Unknown | Novel |
| PSGen 28 | Unknown | Novel |
| PSGen 29 | Unknown | Novel |
*
PEGen are progression-elevated genes that display elevated expression in E11-NMT versus E11 cells. PSGen are progression suppressed genes that display elevated expression in E11 versus E11-NMT cells.
†
Sequences have been compared with reported genes in various DNA data bases (including GenBank and the European Molecular Biology Laboratory), and identifications with known genes are indicated. Genes without homology to currently reported genes are indicated as unknown.
‡
Percentage homology with known sequences, either human, rat, or mouse, is indicated. Where no homology exists, the cDNA is considered novel.